U.S. Markets closed

Seattle Genetics, Inc. (SGEN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
54.39+0.25 (+0.46%)
At close: 4:00PM EDT

54.29 -0.10 (-0.18%)
After hours: 6:15PM EDT

People also watch
  • Have held this stock for many years. Sold off a smaller portion recently to take a profit. Any opinions on 1-2 year prospects in view of recent sgn-33a discontinuation and less than riveting Echelon-1 results? Do these recent developments make a buyout over this period more or less likely?....and at what level?

    I welcome well thought out speculation and observations. Thanks!
  • SGEN in a great position to day trade again. Load the boat! $20.00 off it's high. When JUNO tanked it was also a sure thing. Already gained back 10 bucks off its low. These bio stocks can be huge money makers if you SELL on the rapid rise and re-enter on huge dips. Remember BLUE?
  • SGEN bottom is in. Let's look for a turn around after earning report. Exciting news is near the end of the year and early next year.
    Have a great week!
  • WIll ride this one all year.
  • Well, we may be hurting a bit lately. But thank god, Clay can still feed his family. He made a cool $924,000 this week through his latest round of options sales.
  • SGEN bought Clay a pretty impressive home with all those free shares. I posted on this board a couple years ago about bio tech company CEO's homes and many of those so called bio tech's are banko. Remember the one I posted where the house slid down this hill? SGEN is not one of those scam startups so that is not what I am saying so Red, save the ink.
  • SEAGEN reported a 8.2% stake in IMMU.
  • What kills me about SGEN is their long history of poor messaging. The recent E-1 press release and conference call were a disaster. In the press release they highlighted neutropenia and neuropathy as toxs associated with introduction of the ADC into frontline but make no mention of the reduced pulmonary tox associated with removal of bleomycin only an increased risk in the control arm. The first two toxs have always been associated with Adcetris and as you know clear rapidly after treatment cessation. The pulmonary tox is scarring and lasts a lifetime. Why highlight it the first two toxicities they are already known? The first thing the media does is talk about new toxicities instead of highlighting the reversal of pulmonary tox. It’s a huge misstep and completely changed the sentiment of the press release to the media and traders.
    They also fail to highlight their collaborators success. They have a breakthrough designation in Europe for DLBCL and it was never mentioned. I had to dig it up and highlight it on the board. They must have known that was coming. It could have even been mentioned the E-1 press release.
    The executive committee has a duty to properly frame the messaging of their important improvements of their life saving therapies. It’s not as if they are making stuff up to goose the stock. They just need to highlight the actual data.
    It's almost as if they want the stock price to be suppressed. It's like Clay is purposefully disregarding his fiduciary duties to get lower share prices for options. I can't figure it out. At this point it's either gross incompetence or criminally negligent.
  • If it sinks to $50, time to unload big time.
    Relative strength is poor
  • Marriage is the triumph of imagination over intelligence. http://dataunion.tistory.com/3192

    Seattle Genetics NASDAQ : SGEN Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.5 In other words, the correlation coefficient of the other stock
  • Is management going to allow the shorts to bleed the share price below $50 on low volume?
    I hope they wake up soon.
  • The posters on this board for the last 3 years were saying this was going to be bought out at $70.00 a share. When the stock finally reached $70.00 (the big goal) you still held?
  • Genentech's ADC 79b in DLBCL utilizing SGENs linker got Prime Status at the EMA. Similar to FDAs breakthrough designation.
    Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU
    The European Medicines Agency (EMA) granted PRIME (PRIorityMEdicines) designation to Roche Holdings AG 's RHHBY investigational drug polatuzumab.
  • Echelon results are out. No 90% or greather but 82% without lung issue (long term terrible from personal knowledge) is still very good. Market reaction is same as when Adcetris received initial FDA approval. CC is either 8:30 this AM (Forbes) or 5:30 this PM (AP)
    Talking about snatching defeat from the jaws of victory.
  • We hv heard from Red yet.
    Are you still here?
  • Whomever is buying now is going to make a lot of dough in a couple of days.
  • New adcetris data in GVHD. "BV is tolerable and has activity in steroid-refractory acute GVHD and merits further
    investigation. " Big market.


  • I bought a fresh batch of sgen at around 55. 💵🤑💵
  • Hey Satnam, bio sector is ticking up along with SGEN. Better cover your short and cut your losses before you lose your house.
  • *Seattle Genetics Inc /Wa CMO & EVP, R & D Drachman Jonathan G Sold 10,000 Shares With Price Range $64.00 ~ $64.58 on 06/22/2017 - [SGEN]

    Mon Jun 26 20:19:00 2017 EDT